2024 has been an incredibly busy year for Norstella as its constituent organizations – Citeline, Evaluate, MMIT, Panalgo, and the Dedham Group – have continued to support the biopharma ecosystem in bringing new therapies to patients. Throughout the course of the year, we have also shared our latest views on the issues that are most critical to our clients. This white paper distills a selection of these analyses into a single piece of research that describes our perspectives and shapes our strategy heading into 2025.
Three key themes emerge, that we will explore further in this white paper.
- An abundance of R&D creates a productivity and attrition challenge
- Pharmaceutical companies will differentiate from each other on the strength of their portfolio decision-making
- Early market access strategy is essential to protect pharma’s bottom line in response to dynamics across the value chain
Please read the full report to learn more or contact us to explore any of the themes discussed in further detail.
